Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
London Centre for Nanotechnology, University College London, London, United Kingdom; Department of Chemistry, University College London, London, United Kingdom
Qiaoying Wang
Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Nicolas J Roth
Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
Jessica Gibson
Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Ariana Samadi
Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Hemant M Kocher
Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
London Centre for Nanotechnology, University College London, London, United Kingdom; Department of Chemistry, University College London, London, United Kingdom
Pancreatic ductal adenocarcinoma (PDAC) continues to show no improvement in survival rates. One aspect of PDAC is elevated ATP levels, pointing to the purinergic axis as a potential attractive therapeutic target. Mediated in part by highly druggable extracellular proteins, this axis plays essential roles in fibrosis, inflammation response, and immune function. Analyzing the main members of the PDAC extracellular purinome using publicly available databases discerned which members may impact patient survival. P2RY2 presents as the purinergic gene with the strongest association with hypoxia, the highest cancer cell-specific expression, and the strongest impact on overall survival. Invasion assays using a 3D spheroid model revealed P2Y2 to be critical in facilitating invasion driven by extracellular ATP. Using genetic modification and pharmacological strategies, we demonstrate mechanistically that this ATP-driven invasion requires direct protein-protein interactions between P2Y2 and αV integrins. DNA-PAINT super-resolution fluorescence microscopy reveals that P2Y2 regulates the amount and distribution of integrin αV in the plasma membrane. Moreover, receptor-integrin interactions were required for effective downstream signaling, leading to cancer cell invasion. This work elucidates a novel GPCR-integrin interaction in cancer invasion, highlighting its potential for therapeutic targeting.
